Treace Medical Concepts (TMCI)
NASDAQ:TMCI
Want to see TMCI full AI Analyst Report?
TMCI Stock Chart & Stats
$1.94
-$0.15(-1.96%)
At close: 4:00 PM EST
$1.94
-$0.15(-1.96%)
Day’s Range― - ―
52-Week Range$1.17 - $7.78
Previous CloseN/A
Volume76.56K
Average Volume (3M)918.48K
Market Cap
$253.65M
Enterprise Value$228.47M
Total Cash (Recent Filing)$51.85M
Total Debt (Recent Filing)$13.55M
Price to Earnings (P/E)―
Beta2.57
Next Earnings
Aug 11, 2026EPS Estimate
-0.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.97
Shares Outstanding64,872,980
10 Day Avg. Volume1,009,218
30 Day Avg. Volume918,480
Financial Highlights & Ratios
PEG Ratio-0.79
Price to Book (P/B)1.77
Price to Sales (P/S)0.73
P/FCF Ratio-5.26
Enterprise Value/Market Cap0.90
Enterprise Value/Revenue1.10
Enterprise Value/Gross Profit1.38
Enterprise Value/Ebitda-4.93
Forecast
1Y Price Target
$4.50Price Target Upside131.96% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.9
Revenue Forecast (FY)$206.33M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsSustained ~80% gross margins reflect a high-value implant/consumable business with strong product-level profitability. This margin tailwind provides durable operating leverage as volume scales, supports reinvestment in commercialization, and offers resilience to modest pricing pressure.
Portfolio & TAM ExpansionIntroducing multiple systems and Q3 commercialization of SuperBite/SpeedXM expands the addressable market by roughly $300M. Broader product breadth reduces single-product dependency, increases cross-sell and long-term consumable demand, and materially improves structural growth opportunity.
Surgeon Adoption & Procedure GrowthA growing installed base (3,300+ surgeons) and accelerating uptake of new systems indicate durable clinical adoption and pull-through of implants/consumables. As trained surgeons perform repeat procedures, recurring per-case sales create a steady revenue foundation over time.
Bears Say
Persistent Negative Cash FlowConsistent negative operating and free cash flow means the business remains reliant on external financing and is eroding equity. Even with narrowed burn, sustained cash deficits constrain investment flexibility and elevate execution risk until internal cash generation turns positive.
Top-line WeaknessManagement's guidance indicating flat-to-down revenue for FY‑2026 and a Q1 YoY decline signals persistent demand or mix issues. Prolonged top-line softness limits operating leverage, delays profitability, and increases dependence on successful commercialization to restore growth.
ASP / Mix HeadwindsA structural shift toward lower-priced minimally invasive systems reduces revenue per case even as procedure counts rise. This mix dynamic compresses revenue growth and delays margin flow-through, requiring sustained higher case volumes or pricing/mix recovery to restore prior revenue levels.
Treace Medical Concepts News
TMCI FAQ
What was Treace Medical Concepts’s price range in the past 12 months?
Treace Medical Concepts lowest stock price was $1.17 and its highest was $7.78 in the past 12 months.
What is Treace Medical Concepts’s market cap?
Treace Medical Concepts’s market cap is $253.65M.
When is Treace Medical Concepts’s upcoming earnings report date?
Treace Medical Concepts’s upcoming earnings report date is Aug 11, 2026 which is in 59 days.
How were Treace Medical Concepts’s earnings last quarter?
Treace Medical Concepts released its earnings results on May 08, 2026. The company reported -$0.28 earnings per share for the quarter, beating the consensus estimate of -$0.308 by $0.028.
Is Treace Medical Concepts overvalued?
According to Wall Street analysts Treace Medical Concepts’s price is currently Undervalued.
Does Treace Medical Concepts pay dividends?
Treace Medical Concepts does not currently pay dividends.
What is Treace Medical Concepts’s EPS estimate?
Treace Medical Concepts’s EPS estimate is -0.3.
How many shares outstanding does Treace Medical Concepts have?
Treace Medical Concepts has 64,872,980 shares outstanding.
What happened to Treace Medical Concepts’s price movement after its last earnings report?
Treace Medical Concepts reported an EPS of -$0.28 in its last earnings report, beating expectations of -$0.308. Following the earnings report the stock price went up 4.687%.
Which hedge fund is a major shareholder of Treace Medical Concepts?
Currently, no hedge funds are holding shares in TMCI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Treace Medical Concepts Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.50 (131.96% Upside)
$4.50 (131.96% Upside)
Hedge Fund Trend
Decreased
By 1.7M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $1.1M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-65.80%
12-Months-Change
Fundamentals
Return on Equity
-69.50%
Trailing 12-Months
Asset Growth
-10.56%
Trailing 12-Months
Company Description
Treace Medical Concepts
Headquartered in Ponte Vedra Beach, Florida, Treace Medical Concepts, Inc. is an orthopedic medical device enterprise that specializes in the development, manufacturing, and commercialization of surgical tools for foot and ankle specialists throughout the United States. A cornerstone of its product line is the Lapiplasty procedure, which enables surgeons to comprehensively correct bunions in all three dimensions, thereby offering patients significant cosmetic and medical benefits. The firm also provides the Lapiplasty Mini-Incision precision system. Furthermore, its portfolio includes instruments designed to facilitate various ancillary surgical procedures, such as akin osteotomies, weil osteotomies, intercuneiform stabilization, lesser tarsometatarsal joint fusions, autograft bone harvesting, and MTP fusion. Treace Medical Concepts, Inc. was established in 2013.
TMCI Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presents a mixed picture: commercial execution and product momentum are clear positives (rapid adoption of new systems, expanding TAM, high gross margins, improved cash balance and reduced cash burn expectations), but near-term financials remain challenged (Q1 revenue down 10%, larger net and EBITDA losses, and ASP/mix headwinds). Management is taking a conservative posture—reaffirming guidance while highlighting the path to lapping mix headwinds in the back half of 2026 and expecting revenue growth to return in Q4. Overall, operational improvements and promising adoption trends offset but do not yet fully overcome the near-term revenue and profitability headwinds, leaving the situation balanced between encouraging commercial traction and ongoing financial pressure.View all TMCI earnings summariesTMCI Stock 12 Month Forecast
Average Price Target
$4.50
▲(131.96% Upside)
Technical Analysis
Ownership Overview
28.33% Insiders
8.21% Mutual Funds
20.48% Other Institutional Investors
36.16% Public Companies and
Individual Investors